Cellectar Biosciences, Inc. (NASDAQ: CLRB)

Cellectar Biosciences, Inc. (CLRB) is a company that operates in the biopharmaceutical industry, with a specific focus on the discovery, development, and commercialization of drugs for cancer treatment. The company's primary objective is to leverage its proprietary phospholipid ether (PLE) drug conjugate (PDC) delivery platform to develop PDCs that target cancer cells, thereby improving efficacy and safety through fewer off-target effects.

Cellectar's PDC platform is designed to provide selective delivery of a diverse range of oncologic payloads to cancerous cells, regardless of whether they are hematologic cancers or solid tumors, primary tumors or metastatic tumors, or cancer stem cells. The platform takes advantage of a metabolic pathway (beta oxidation) that is utilized by nearly all tumor cell types in all stages of the tumor cycle. Tumor cells modify the cell membrane to create specific, highly organized microdomains, allowing for the transport of lipids and long-chain fatty acids into the cytoplasm. The PDCs then bind to these regions and enter the intracellular compartment directly.

Cellectar's lead PDC therapeutic, iopofosine I 131, is a small-molecule PDC that delivers iodine-131 directly to cancer cells while limiting exposure to healthy cells. Iopofosine I 131 has been evaluated in several clinical trials, including the completed CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory Waldenstrom's macroglobulinemia (WM), the ongoing Phase 2b study in relapsed/refractory multiple myeloma (MM) and central nervous system lymphoma (CNSL) patients, and the CLOVER-2 Phase 1b study for pediatric patients with high-grade gliomas.

The CLOVER-WaM study met its primary endpoint, with a major response rate (MRR) of 61% (95% confidence interval [44.50%, 75.80%], two-sided p value < 0.0001)), which exceeded the agreed-upon statistical hurdle of 20%. The overall response rate (ORR) in evaluable patients was 75.6%, and 100% of patients experienced disease control. Responses were durable, with a median duration of response not reached and 76% of patients remaining progression-free at a median follow-up of eight months.

Cellectar has received several designations and grants from the National Cancer Institute (NCI) and the FDA, including Fast Track Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation. The company's PDC platform has the potential to treat a broad range of cancers, including hematologic cancers, solid tumors, and brain tumors.

Cellectar has established three ongoing collaborations featuring four unique payloads and mechanisms of action. Through research and development collaborations, the company's strategy is to generate near-term capital, supplement internal resources, gain access to novel molecules or payloads, accelerate product candidate development, and broaden its proprietary and partnered product pipelines.

In addition to iopofosine I 131, Cellectar is developing other PDCs, including CLR 12120, a radio-conjugate program, and a series of proprietary small molecule phospholipid drug conjugates. These programs employ either novel payloads or novel linkers. Many of these molecules have demonstrated efficacy and tolerability in preclinical mouse models.

The company's technology overview highlights the basis for selective tumor targeting of its compounds, which lies in differences between the plasma membranes of cancer cells as compared to those of most normal cells. Data suggests that lipid rafts serve as portals of entry for PDCs such as iopofosine and the company's multiple series of drug conjugates. The marked selectivity of the company's compounds for cancer cells versus non-cancer cells likely results from cancer cells' maintenance of an overabundance of lipid rafts and the stabilization of these microdomains within the plasma membrane as compared to normal cells.